The pharmaceutical group Novartis has given, as part of a drug donation, to the Ministry of Health in Morocco, a significant amount of hydroxychloroquine in order to support its fight against the current pandemic and contribute to the treatment of Moroccan patients suffering from Covid-19. Morocco is one of the first countries in the Middle East and Africa to receive a donation of this drug.
This donation comes at a time when Novartis has been mobilizing its efforts since the beginning of the pandemic to come to the aid, through citizen actions, of patients, professionals of the sector and public health authorities in Morocco. Novartis notably joined the association of multinational pharmaceutical companies to contribute to a global financial donation intended for the special Covid-19 fund set up on the High Instructions of His Majesty King Mohammed VI.
In addition, and internationally, Novartis has announced several initiatives to support the overall response to the pandemic. The group is currently conducting a large-scale study on hydroxychloroquine in the United States and has joined two major research initiatives: the therapeutic accelerator Covid-19 coordinated by the Bill & Melinda Gates Foundation, Wellcome and Mastercard, as well as a research partnership launched by the Innovative Medicines Initiative. These two programs translate into intersectoral collaborations that bring together pharmaceutical companies and expert academic institutions in coordinated research programs whose objective is to accelerate research around the most promising molecules.
In parallel and in response to the urgent call from the European Federation of Pharmaceutical Industries and Associations, Novartis has made available several compounds considered suitable for in vitro antiviral testing. The group is evaluating other existing products to see if their use can be extended beyond their current indications during the pandemic.
Fully mobilized, Novartis pursues a responsible business approach in accordance with its mission: to reinvent medicine to improve and prolong life. The group thus operates, in close collaboration with all players in the healthcare system, in order to develop innovative drugs that improve the lives of patients.